This study also suggested that when a therapeutic strategy targeting on JNK2 signaling was designed, the phosphorylation status of JNK2 in cancer cells should be considered, since that might affect the therapeutic outcomes for the breast cancer patients even with the similar molecular subtype. This evidence concerns the gene MAPK9 and cancer.